Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement